CD8A and neoplasm: Consistent with its costimulatory activity, agonistic mAbs against CD137 have mounted effective antitumor effects in multiple preclinical models (9–11) that have been mainly attributed to the reinvigoration of dysfunctional CD8+ tumor-infiltrating lymphocytes (TILs) (12, 13).